IShares funds are powered by the expert portfolio and risk management of BlackRock. No information on this Website constitutes business, financial, investment, trading, tax, legal, regulatory, accounting or any other advice. If you are unsure about the meaning of any information provided, please consult your financial or other professional adviser. The big EHR players sit somewhere in the middle, helping enterprise clients build out AI architecture with multiple use cases per organization. The consumer mandate vs. the expectation gapThe consumer sits in the center of the new health care ecosystem.

• By their nature, forward-looking statements are subject to numerous assumptions, risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.
• This merger uniquely combined a wellness company with a Third-Party Administrator (TPA), creating a synergistic relationship between employer and payer customers, all focused on reducing employee healthcare costs.
• While each region accounted for roughly one-third of global deal volumes, Asia Pacific grew the most, up 12% in 2025, compared to a 5% increase in Europe, the Middle East, and Africa (EMEA) and a drop of 23% in the Americas.
• The model is restricted to authorized security researchers and government agencies due to its potential for weaponization by malicious actors.

Opportunity Amid Complexity: How Healthcare Investors May Win in 2026

Beyond drug pipelines, hospital and health system M&A is also reshaping access and diagnostics. Hospitals are consolidating to gain access to patients and considering acquiring labs to run diagnostic testing for physician offices. The debate over drug pricing is increasingly shaped by policy proposals like Most Favored Nation (MFN), which would peg U.S. reimbursement to the lowest prices paid globally. Companies argue that Europe, where prices are lowest, is not a favorable benchmark because reimbursement there often takes years, while high clawback rates and mandatory rebates act as taxes on revenue.

• In HCIT, AI-enabled RCM bolt-on tools are absorbing coding and denials work that once required offshore labor.
• Yahoo News reports that Anthropic’s unreleased Mythos model raises critical questions about who should decide when powerful AI systems are ready for public deployment.
• This has already started with the AI buildout being increasingly debt funded, as seen from bond sales by large tech firms.
• Carefully consider the Funds’ investment objectives, risk factors, and charges and expenses before investing.
• Healthcare private equity reached a record high in global deal value in 2025, powered by large transactions and overcoming a slowdown in the second quarter in both North America and Asia-Pacific.

How KPMG can help

In fact, https://alahomemaster.com/neo-hair-transplant-hair-transplant-clinic-in-istanbul-and-its-advantages.html KPMG LLP was the first of the Big Four firms to organize itself along the same industry lines as clients. The ability to improve patient experience while reducing costs is incredibly powerful. Pharma services, particularly CROs and CDMOs, should rebound as clinical trial activity increases. The intersection of healthcare and technology has the power to improve outcomes, lower costs, and meaningfully improve the patient and caregiver experience. Technology adoption by clinicians, payers, and consumers will determine where profit pools shift. That creates both opportunity and risk, making technology one of the most important variables investors are watching.

• The political battle over expiring ACA subsidies, the Trump administration’s proposed outline for healthcare and the ongoing political question of what Medicaid and Medicare will (and will not) cover all make 2026 a year of potential upheaval.
• Interest rate cuts by the US Federal Reserve that began in 2024 were paused through much of 2025 before being restarted late in the year.
• The reports serve as critical tools to inform national strategies and shape global dialogue ahead of the 2025 United Nations High-Level Meeting on noncommunicable diseases and promotion of mental health and well-being, taking place in New York on 25 September 2025.
• Meanwhile, the U.S. system faces long-term challenges like nursing and provider shortages, high turnover, unreliable care for rural populations and an aging population.

AI Marketplaces Reshape Editorial Advertising with Direct Assistant Integration

We see buyers prioritizing assets that enable automation, revenue cycle optimization, and value-based care delivery. Despite the value dip, the sector is buoyed by long-term tailwinds in digital transformation and care decentralization. Strategic buyers continued to dominate, accounting for 60.2 percent of deal volume, while private equity (PE) activity remained resilient despite tighter credit markets. H1’25 was defined by platform-building, renewed focus on value-based care, AI-driven healthtech, and outpatient expansion. Notably, the sector saw a resurgence in healthcare services consolidation, high activity in digital health deals, and a flurry of activity in healthcare logistics and hybrid care delivery.

We think recent developments, including the disruption to energy supply reinforce the U.S. edge in AI. The AI theme is also powering corporate earnings upgrades in emerging market (EM) stocks too. Before the conflict, markets were pricing at least two quarter-point interest rate cuts from the Federal Reserve in 2026.

Market Dynamics

Recent deals such as Novartis’s $12bn acquisition of Avidity Biosciences, Merck’s $10bn acquisition of Verona Pharma, Roche’s $3.5bn acquisition of 89bio, and Sanofi’s $2.2bn acquisition of Dynavax illustrate the size and scale of deals we expect to see in 2026. Activity is expected to remain focused on acquisitions that strengthen and complement treatment portfolios while accelerating innovation. The M&A landscape is expected to see a gradual increase in activity throughout the year. High-quality assets in all categories, especially in HCIT, are moving quickly at strong valuations. Technology-enabled services that have developed unique or market-leading platforms are particularly attractive.

Industry analysts note that Google is building its AI lead not only through the flagship Gemini models but also through open models like Gemma 4, which help establish the company’s technology as a development standard while enabling more widespread AI deployment. Google has released Gemma 4, its most advanced open-weights AI model family built on the same architectural foundation as Gemini 3. The models are specifically designed to handle complex reasoning tasks and support autonomous AI agents running locally on low-power devices such as workstations and smartphones, representing a significant advancement in edge AI capabilities. The practice, dubbed ‘recommendation poisoning,’ involves creating content specifically designed to appear authoritative to AI systems while promoting particular products or services. This represents a significant challenge for AI search accuracy, as traditional ranking algorithms are being circumvented by content crafted to exploit how large language models process and prioritize information sources. Meta is reportedly planning to open source its upcoming AI models as the company continues to struggle with user adoption of its current AI offerings.